{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:21:03Z","timestamp":1791580863057,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40120-022-00341-z","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T17:02:15Z","timestamp":1647190935000},"page":"741-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab"],"prefix":"10.1007","volume":"11","author":[{"given":"Anne H.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Davydovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A. C.","family":"Cree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Totolyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratnakar","family":"Pingili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mancione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseanne","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Zielman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayan Das","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,13]]},"reference":[{"issue":"3","key":"341_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","volume":"35","author":"AT Reder","year":"2021","unstructured":"Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, et al. COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs. 2021;35(3):317\u201330.","journal-title":"CNS Drugs"},{"key":"341_CR2","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) dashboard. 2021. https:\/\/covid19.who.int\/. Accessed 17 Jan 2022."},{"key":"341_CR3","doi-asserted-by":"crossref","unstructured":"Gazit. Comparing SARS-CoV-2 Natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. 2021. https:\/\/ncrc.jhsph.edu\/research\/comparing-sars-cov-2-natural-immunity-to-vaccine-induced-immunity-reinfections-versus-breakthrough-infections\/. Accessed 13 Jan 2022.","DOI":"10.1101\/2021.08.24.21262415"},{"issue":"46","key":"341_CR4","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.15585\/mmwr.mm7046a4","volume":"70","author":"AL Naleway","year":"2021","unstructured":"Naleway AL, Groom HC, Crawford PM, Salas SB, Henninger ML, Donald JL, et al. Incidence of SARS-CoV-2 infection, emergency department visits, and hospitalizations because of COVID-19 among persons aged \u226512 Years, by COVID-19 vaccination status - Oregon and Washington, July 4-September 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(46):1608\u201312.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"341_CR5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1177\/1352458516681198","volume":"23","author":"JM Wijnands","year":"2017","unstructured":"Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, et al. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler. 2017;23(11):1506\u201316.","journal-title":"Mult Scler"},{"issue":"4","key":"341_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","volume":"12","author":"A Winkelmann","year":"2016","unstructured":"Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12(4):217\u201333.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"341_CR7","doi-asserted-by":"publisher","first-page":"e14627","DOI":"10.1111\/dth.14627","volume":"34","author":"A Druyan","year":"2021","unstructured":"Druyan A, Lidar M, Brodavka M, Levy I, Barzilai A, Pavlotsky F. The risk for severe COVID 19 in patients with autoimmune and\/or inflammatory diseases: first wave lessons. Dermatol Ther. 2021;34(1):e14627.","journal-title":"Dermatol Ther"},{"issue":"2","key":"341_CR8","first-page":"68","volume":"3","author":"F Chaudhry","year":"2021","unstructured":"Chaudhry F, Jageka C, Levy PD, Cerghet M, Lisak RP. Review of the COVID-19 risk in multiple sclerosis. J Cell Immunol. 2021;3(2):68\u201377.","journal-title":"J Cell Immunol"},{"key":"341_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117776","author":"L Prosperini","year":"2021","unstructured":"Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. J Neurol. 2021. https:\/\/doi.org\/10.1016\/j.jns.2021.117776.","journal-title":"J Neurol"},{"issue":"6","key":"341_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","volume":"78","author":"A Salter","year":"2021","unstructured":"Salter A, Fox RJ, Newsome SD, Halper J, Li DKB, Kanellis P, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699\u2013708.","journal-title":"JAMA Neurol"},{"key":"341_CR11","doi-asserted-by":"publisher","first-page":"102725","DOI":"10.1016\/j.msard.2020.102725","volume":"49","author":"R Hughes","year":"2021","unstructured":"Hughes R, Whitley L, Fitovski K, Schneble HM, Muros E, Sauter A, et al. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord. 2021;49:102725.","journal-title":"Mult Scler Relat Disord."},{"key":"341_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012753","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000012753.","journal-title":"Neurology"},{"issue":"4","key":"341_CR13","doi-asserted-by":"publisher","first-page":"e1001","DOI":"10.1212\/NXI.0000000000001001","volume":"8","author":"M Barzegar","year":"2021","unstructured":"Barzegar M, Mirmosayyeb O, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, et al. COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1001.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"4","key":"341_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.7224\/1537-2073.2020-037","volume":"22","author":"S Thakolwiboon","year":"2020","unstructured":"Thakolwiboon S, Zhao-Fleming H, Pan J, Scott JK, Shoji E, Sohn G, et al. Disease-modifying therapies during the COVID-19 outbreak: a narrative review of international and national recommendations. Int J MS Care. 2020;22(4):151\u20137.","journal-title":"Int J MS Care"},{"issue":"3_Suppl","key":"341_CR15","first-page":"46","volume":"26","author":"A Garjani","year":"2020","unstructured":"Garjani A, Evangelou N, Das Nair R, Hunter R, Tuite-Dalton K, Coles A, et al. COVID-19 in people with MS: a large community-based study of the UK MS register. Mult Scler J. 2020;26(3_Suppl):46\u20137.","journal-title":"Mult Scler J"},{"key":"341_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-326904","author":"C Louapre","year":"2021","unstructured":"Louapre C, Ibrahim M, Maillart E, Abdi B, Papeix C, Stankoff B, et al. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2021. https:\/\/doi.org\/10.1136\/jnnp-2021-326904.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"22","key":"341_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1212\/WNL.0000000000009507","volume":"94","author":"W Brownlee","year":"2020","unstructured":"Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020;94(22):949\u201352.","journal-title":"Neurology"},{"issue":"5","key":"341_CR18","doi-asserted-by":"publisher","first-page":"e1035","DOI":"10.1212\/NXI.0000000000001035","volume":"8","author":"L Rolfes","year":"2021","unstructured":"Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, et al. Ocrelizumab Extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1035.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"341_CR19","doi-asserted-by":"publisher","first-page":"103636","DOI":"10.1016\/j.ebiom.2021.103636","volume":"73","author":"SP Gadani","year":"2021","unstructured":"Gadani SP, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith MD, et al. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine. 2021;73:103636.","journal-title":"EBioMedicine"},{"key":"341_CR20","doi-asserted-by":"publisher","first-page":"103251","DOI":"10.1016\/j.msard.2021.103251","volume":"56","author":"F Novak","year":"2021","unstructured":"Novak F, Nilsson AC, Nielsen C, Holm DK, \u00d8stergaard K, Bystrup A, et al. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103251.","journal-title":"Mult Scler Relat Disord"},{"key":"341_CR21","doi-asserted-by":"publisher","first-page":"103581","DOI":"10.1016\/j.ebiom.2021.103581","volume":"72","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021;72:103581.","journal-title":"EBioMedicine"},{"key":"341_CR22","unstructured":"World Health Organization. Archived: WHO timeline-COVID-19. 2022. https:\/\/www.who.int\/news\/item\/27-04-2020-who-timeline---covid-19. Accessed 13 Jan 2022."},{"key":"341_CR23","first-page":"223","volume":"0218","author":"E Fox","year":"2020","unstructured":"Fox E, Mayer L, Aungst A, Mancione L, Rennie N, Roustan A, Stoneman D, Su W, Gupta A, Zalesak M, Ziehn M, Robertson D, Cohen J. Long-term safety, compliance, and effectiveness of ofatumumab in patients with relapsing multiple sclerosis: The ALITHIOS Phase 3b study. Jt ACTRIMS-ECTRIMS Meet (Virtual). 2020;0218:223\u2013659.","journal-title":"Jt ACTRIMS-ECTRIMS Meet (Virtual)."},{"key":"341_CR24","unstructured":"Medicine USNLO. Long-term safety, tolerability and effectiveness study of ofatumumab in patients with relapsing MS (ALITHIOS). 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03650114. Accessed 17 Dec 2021."},{"key":"341_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211044479","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2021. https:\/\/doi.org\/10.1177\/13524585211044479.","journal-title":"Mult Scler"},{"key":"341_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211055934","author":"JI Kira","year":"2021","unstructured":"Kira JI, Nakahara J, Sazonov DV, Kurosawa T, Tsumiyama I, Willi R, et al. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study. Mult Scler. 2021. https:\/\/doi.org\/10.1177\/13524585211055934.","journal-title":"Mult Scler"},{"issue":"6","key":"341_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, H\u00e4ring DA, Ramanathan K, Merschhemke M, Kappos L, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"key":"341_CR28","unstructured":"European Medicines Agency (EMA). ICH guideline E2B (R3) on electronic transmission of individual case safety reports (ICSRs)-data elements and message specification-implementation guide. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-4.pdf. Accessed 17 Dec 2021."},{"key":"341_CR29","unstructured":"E2A I. ICH harmonised tripartite guideline clinical safety data management: definitions and standards for expedited reporting E2A. 2022. https:\/\/database.ich.org\/sites\/default\/files\/E2A_Guideline.pdf. Accessed 17 Dec 2021."},{"key":"341_CR30","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2022. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 17 Dec 2021."},{"key":"341_CR31","unstructured":"COVID-19 CVf. Vaccines for COVID-19. 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/effectiveness\/why-measure-effectiveness\/breakthrough-cases.html. Accessed 17 Dec 2021."},{"key":"341_CR32","doi-asserted-by":"publisher","first-page":"102482","DOI":"10.1016\/j.msard.2020.102482","volume":"46","author":"E Maillart","year":"2020","unstructured":"Maillart E, Papeix C, Lubetzki C, Roux T, Pourcher V, Louapre C. Beyond COVID-19: DO MS\/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? Mult Scler Relat Disord. 2020;46:102482.","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"341_CR33","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/acn3.51408","volume":"8","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, et al. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol. 2021;8(8):1738\u201344.","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"341_CR34","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3390\/jcm9124067","volume":"9","author":"N Mohn","year":"2020","unstructured":"Mohn N, Konen FF, Pul R, Kleinschnitz C, Pruss H, Witte T, et al. Experience in multiple sclerosis patients with covid-19 and disease-modifying therapies: a review of 873 published cases. J Clin Med. 2020;9(12):4067.","journal-title":"J Clin Med"},{"key":"341_CR35","unstructured":"Cross AH, Delgado S, Habek M, Davydovskaya M, Ward BJ, Cree BAC, Totolyan N, Pingili R, Mancione L, Sullivan R, Su W, Zielman R, Das Gupta A, Montalban X, Winthrop K. Outcomes of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab: data from the ALITHIOS study and post marketing surveillance. In: European Committee for Treatment and Research in Multiple Sclerosis-37th Congress; 2021."},{"issue":"16","key":"341_CR36","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97(16):e1546\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000012700.","journal-title":"Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis Neurology."},{"key":"341_CR37","unstructured":"Jasi\u0144ska E, Habek M, Wynn D, Dunphy S, Mancione L, Rennie N, Su W, Zielman R, Delgado S. Impact of ofatumumab on immune responses post-vaccination in RMS patients: ALITHIOS vaccination substudy design. In: Presented at 7th Congress of the European Academy of Neurology, (Virtual); June 19\u201322, 2021, OPR-207."},{"key":"341_CR38","first-page":"233","volume":"P0236","author":"H Wiendl","year":"2020","unstructured":"Wiendl H, Seze J, Bar-Or A, Correale J, Cross A, Kappos L, Selmaj K, Gupta A, H\u00e4ring D, Jehl V, Kerloeguen C, Pingili R, Su W, Sullivan R, Zalesak M, Hauser S. Serum immunoglobulin levels and infection risk in the Phase 3 trials of ofatumumab in relapsing multiple sclerosis. Jt ACTRIMS-ECTRIMS Meet (Virtual). 2020;P0236:233\u2013659.","journal-title":"Jt ACTRIMS-ECTRIMS Meet (Virtual)"},{"key":"341_CR39","doi-asserted-by":"publisher","first-page":"103004","DOI":"10.1016\/j.msard.2021.103004","volume":"52","author":"F Alshamrani","year":"2021","unstructured":"Alshamrani F, Alnajashi H, AlJumah M, Almuaigel M, Almalik Y, Makkawi S, et al. Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia. Mult Scler Relat Disord. 2021;52:103004.","journal-title":"Mult Scler Relat Disord"},{"key":"341_CR40","doi-asserted-by":"publisher","first-page":"577788","DOI":"10.1016\/j.jneuroim.2021.577788","volume":"362","author":"I Adamec","year":"2022","unstructured":"Adamec I, Rogi\u0107 D, Penz MG, Braun C, Habek M. Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab. J Neuroimmunol. 2022;362:577788.","journal-title":"J Neuroimmunol"},{"key":"341_CR41","doi-asserted-by":"publisher","first-page":"204209862093859","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;11:2042098620938595.","journal-title":"Ther Adv Drug Saf"},{"issue":"11","key":"341_CR42","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990\u20132001. https:\/\/doi.org\/10.1038\/s41591-021-01507-2.","journal-title":"Nat Med."},{"key":"341_CR43","unstructured":"European Medicines Agency. International Conference on Harmonisation: Guideline for good clinical practice E6(R2). 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf. Accessed 13 Jan 2022."},{"key":"341_CR44","unstructured":"World Medical Association. WMA Declaration of Helsinki\u2014ethical principles for medical research involving human subjects. 2018. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 13 Jan 2022."}],"updated-by":[{"DOI":"10.1007\/s40120-022-00346-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00341-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00341-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00341-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T14:34:49Z","timestamp":1652279689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00341-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,13]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["341"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00341-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,13]]},"assertion":[{"value":"26 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-022-00346-8","URL":"https:\/\/doi.org\/10.1007\/s40120-022-00346-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}